• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Verispan Awarded Contract to Provide Data to U.S. Food and Drug Administration

Posted on: Thursday, 8 September 2005, 18:00 CDT

Seventh graph of the release should read: For more information, please contact Jody Fisher at 800-982-5613...(sted For more information, please contact Jody Fisher at 900-982-5613...).

The corrected release reads:

VERISPAN AWARDED CONTRACT TO PROVIDE DATA TO U.S. FOOD AND DRUG ADMINISTRATION

Verispan today announced it has entered a multiyear contract with the U.S. Food and Drug Administration to provide the agency with projected prescription activity and longitudinal patient data in an integrated platform that will be used to monitor trends in the pharmaceutical industry. This marks the first time FDA personnel have access to such data in one system.

Verispan is providing the FDA with real-time access to commercially available longitudinal data. Additionally, Verispan supplies historical, national-level counts of dispensed prescriptions over time. This information is being provided in the following two services:

-- Vector One(TM): National - Verispan's prescription and patient tracking service providing a comprehensive overview of the national performance of all prescription drugs dispensed by retail pharmacies.

-- Vector One(TM): Total Patient Tracker - The first and only service that specifically projects the distinct number of unique patients taking multiple therapies over time.

Verispan is providing FDA personnel with access to a data-extract tool to conduct in-depth analyses of trends shown in the data. Also, the FDA has engaged with Verispan to build a syndicated tool specifically designed to evaluate and report concomitancy across all markets and brands. Development on this initiative is scheduled to begin immediately.

The information and data provided by Verispan will assist the FDA with:

-- Characterizing the duration of exposure to prescription drugs at a de-identified patient level and examining concomitant use of multiple drugs over the same time period

-- Describing national patterns of outpatient drug utilization

-- Assisting in the development of epidemiological drug safety studies

"This alliance represents all that Verispan strives for--to be the partner of choice for key organizations that advance the measurement of healthcare markets," said Peter Bird, Senior Vice President of Strategic Planning and Product Management for Verispan. "We are excited to be able to serve the FDA--and ultimately the public and pharmaceutical industry--by providing timely, integrated prescription and patient-centric data."

Verispan has been providing these services to the FDA since July 29, 2005.

For more information, please contact Jody Fisher at 800-982-5613 or jody.fisher@verispan.com, or Keith Martinek at 781-434-1857 or keith.martinek@verispan.com.

Verispan: The True Measure of Healthcare

Verispan, a healthcare informatics joint venture of Quintiles Transnational Corp. and McKesson Corp., provides a broad array of information products and services to the healthcare industry, including sales targeting and compensation products; market research audits; healthcare profiles; comprehensive managed care offerings; primary market research; opinion leader mapping; data integration, warehousing and mining; data analysis and consulting; direct mail; list services; disease management studies; clinical trial investigator targeting and protocol recruitment evaluation; healthcare outcomes; and cost/benefit analyses, among many others. Verispan is also the nation's leading provider of patient-centric longitudinal data, with dozens of products used by clients spanning the industry.

Headquartered in Yardley, Pa., Verispan employs over 500 dedicated healthcare information professionals. The company's Web site is www.verispan.com

Source: Business Wire

More News in this Category